Kyrgiou Maria, Mitra Anita, Arbyn Marc, Paraskevaidi Maria, Athanasiou Antonios, Martin-Hirsch Pierre P L, Bennett Phillip, Paraskevaidis Evangelos
Surgery and Cancer - West London Gynaecological Cancer Center, Imperial College - Queen Charlotte's & Chelsea, Hammersmith Hospital, Imperial NHS Healthcare Trust, Du Cane Road, London, UK, W12 0HS.
Cochrane Database Syst Rev. 2015 Sep 29;2015(9):CD008478. doi: 10.1002/14651858.CD008478.pub2.
Cervical intra-epithelial neoplasia (CIN) typically occurs in young women of reproductive age. Although several studies have reported the impact that cervical conservative treatment may have on obstetric outcomes, there is much less evidence for fertility and early pregnancy outcomes.
To assess the effect of cervical treatment for CIN (excisional or ablative) on fertility and early pregnancy outcomes.
We searched in January 2015 the following databases: the Cochrane Gynaecological Cancer Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library, Issue 12, 2014), MEDLINE (up to November week 3, 2014) and EMBASE (up to week 52, 2014).
We included all studies reporting on fertility and early pregnancy outcomes (less than 24 weeks of gestation) in women with a history of CIN treatment (excisional or ablative) as compared to women that had not received treatment.
Studies were classified according to the treatment method used and the fertility or early pregnancy endpoint. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated using a random-effects model and inter-study heterogeneity was assessed with I(2). Two review authors (MK, AM) independently assessed the eligibility of retrieved papers and risk of bias. The two review authors then compared their results and any disagreements were resolved by discussion. If still unresolved, a third review author (MA) was involved until consensus was reached.
Fifteen studies (2,223,592 participants - 25,008 treated and 2,198,584 untreated) that fulfilled the inclusion criteria for this review were identified from the literature search. The meta-analysis demonstrated that treatment for CIN did not adversely affect the chances of conception. The overall pregnancy rate was higher for treated (43%) versus untreated women (38%; RR 1.29, 95% CI 1.02 to 1.64; 4 studies, 38,050 participants, very low quality), although the inter-study heterogeneity was considerable (P < 0.01). The pregnancy rates in treated and untreated women with an intention to conceive (88% versus 95%, RR 0.93, 95% CI 0.80 to 1.08; 2 studies, 70 participants, very low quality) and the number of women requiring more than 12 months to conceive (14% versus 9%, RR 1.45, 95% CI 0.89 to 2.37; 3 studies, 1348 participants, very low quality) were no different. Although the total miscarriage rate (4.6% versus 2.8%, RR 1.04, 95% CI 0.90 to 1.21; 10 studies, 39,504 participants, low quality) and first trimester miscarriage rate (9.8% versus 8.4%, RR 1.16, 95% CI 0.80 to 1.69, 4 studies, 1103 participants, low quality) was similar for treated and untreated women, CIN treatment was associated with an increased risk of second trimester miscarriage, (1.6% versus 0.4%, RR 2.60, 95% CI 1.45 to 4.67; 8 studies, 2,182,268 participants, low quality). The number of ectopic pregnancies (1.6% versus 0.8%, RR 1.89, 95% CI 1.50 to 2.39; 6 studies, 38,193 participants, low quality) and terminations (12.2% versus 7.4%, RR 1.71, 95% CI 1.31 to 2.22; 7 studies, 38,208 participants, low quality) were also higher in treated women.The results should be interpreted with caution. The included studies were often small with heterogenous design. Most of these studies were retrospective and of low or very low quality (GRADE assessment) and were therefore prone to bias. Subgroup analyses for the individual treatment methods and comparison groups and analysis to stratify for the cone length was not possible.
AUTHORS' CONCLUSIONS: This meta-analysis suggests that treatment for CIN does not adversely affect fertility, although treatment was associated with an increased risk of miscarriage in the second trimester. These results should be interpreted with caution as the included studies were non-randomised and many were of low or very low quality and therefore at high risk of bias. Research should explore mechanisms that may explain the increase in mid-trimester miscarriage risk and stratify this impact of treatment by the length of the cone and the treatment method used.
宫颈上皮内瘤变(CIN)通常发生于育龄期年轻女性。尽管多项研究报告了宫颈保守治疗对产科结局的影响,但关于生育力及早期妊娠结局的证据却少得多。
评估CIN宫颈治疗(切除或消融)对生育力及早期妊娠结局的影响。
我们于2015年1月检索了以下数据库:Cochrane妇科癌症专业注册库、Cochrane对照试验中心注册库(CENTRAL;Cochrane图书馆,2014年第12期)、MEDLINE(截至2014年11月第3周)及EMBASE(截至2014年第52周)。
我们纳入了所有报告有CIN治疗(切除或消融)史的女性与未接受治疗的女性相比的生育力及早期妊娠结局(妊娠少于24周)的研究。
根据所采用的治疗方法及生育力或早期妊娠终点对研究进行分类。采用随机效应模型计算合并风险比(RR)及95%置信区间(CI),并采用I²评估研究间异质性。两位综述作者(MK、AM)独立评估检索到的论文的入选资格及偏倚风险。然后,两位综述作者比较他们的结果,任何分歧通过讨论解决。若仍未解决,则请第三位综述作者(MA)参与,直至达成共识。
通过文献检索,确定了15项符合本综述纳入标准的研究(2223592名参与者——25008名接受治疗者及2198584名未接受治疗者)。荟萃分析表明,CIN治疗不会对受孕几率产生不利影响。接受治疗的女性总体妊娠率(43%)高于未接受治疗的女性(38%;RR 1.29,95%CI 1.02至1.64;4项研究,38050名参与者,极低质量),尽管研究间异质性相当大(P<0.01)。有受孕意愿的接受治疗和未接受治疗的女性的妊娠率(88%对95%,RR 0.93,95%CI 0.80至1.08;2项研究,70名参与者,极低质量)以及需要超过12个月才能受孕的女性数量(14%对9%,RR 1.45,95%CI 0.89至2.37;3项研究,1348名参与者,极低质量)并无差异。尽管接受治疗和未接受治疗的女性的总流产率(4.6%对2.8%,RR 1.04,95%CI 0.90至1.21;10项研究,39504名参与者,低质量)及孕早期流产率(9.8%对8.4%,RR 1.16,95%CI 0.80至1.69,4项研究,1103名参与者,低质量)相似,但CIN治疗与孕中期流产风险增加相关(1.6%对0.4%,RR 2.60,95%CI 1.45至4.67;8项研究,2182268名参与者,低质量)。接受治疗的女性的异位妊娠数量(1.6%对0.8%,RR 1.89,95%CI 1.50至2.39;6项研究,38193名参与者,低质量)及终止妊娠率(12.2%对7.4%,RR 1.71,95%CI 1.31至2.22;7项研究,38208名参与者,低质量)也更高。应谨慎解释这些结果。纳入的研究往往规模较小且设计各异。这些研究大多为回顾性研究,质量低或极低(GRADE评估),因此容易产生偏倚。无法对个体治疗方法和比较组进行亚组分析,也无法对锥切长度进行分层分析。
本荟萃分析表明,CIN治疗不会对生育力产生不利影响,尽管治疗与孕中期流产风险增加相关。由于纳入的研究为非随机研究,且许多研究质量低或极低,因此存在较高的偏倚风险,应谨慎解释这些结果。研究应探索可能解释孕中期流产风险增加的机制,并根据锥切长度和所采用的治疗方法对治疗的这种影响进行分层。